CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial

• Main Authors: C. Michael Gibson MS, MD (Author), Syed Hassan A. Kazmi MD (Author), Serge Korjian MD (Author), Gerald Chi MD (Author), Adam T. Phillips MD (Author), Sahar Memar Montazerin MD (Author), Danielle Duffy MD (Author), Bo Zheng PhD (Author), Mark Heise PhD (Author), Charles Liss MS (Author), Lawrence I. Deckelbaum MD (Author), Samuel D. Wright PhD (Author), Andreas Gille MD, PhD (Author)
• Format: Book
• Published: SAGE Publishing, 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: Cholesterol efflux capacity (CEC) is impaired following acute myocardial infarction (AMI). CSL112 is an intravenous preparation of human plasma-derived apoA-I formulated with phosphatidylcholine (PC). CSL112 is intended to improve CEC and thereby prevent early recurrent cardiovascular...